Foamix Pharmaceuticals Ltd. (FOMX) Sees Strong Trading Volume
Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw strong trading volume on Monday . 193,198 shares were traded during mid-day trading, an increase of 18% from the previous session’s volume of 163,353 shares.The stock last traded at $8.61 and had previously closed at $8.55.
Several research analysts have recently commented on the company. Zacks Investment Research raised Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $20.00 price target (up from $10.00) on shares of Foamix Pharmaceuticals in a research report on Saturday. Finally, TheStreet raised Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd.
The company’s market capitalization is $263.07 million. The company has a 50-day moving average of $7.35 and a 200-day moving average of $6.65.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.02. The business earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. On average, equities research analysts anticipate that Foamix Pharmaceuticals Ltd. will post ($0.87) earnings per share for the current year.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.